News

New Alopecia Treatment Drug Approved By The FDA

<p style&equals;"font-weight&colon; 400&semi;">The last few months has brought national attention to the hair loss condition known as <a href&equals;"https&colon;&sol;&sol;dev&period;theshaderoom&period;com&sol;jada-pinkett-smith-briefly-addresses-the-oscars-slap-in-new-episode-of-red-table-talk-as-she-focuses-on-alopecia&sol;">alopecia<&sol;a> and there is now some very good news from those who suffer from it&period; According to recent reports&comma; the U&period;S&period; Food and Drug Administration has officially approved a brand new drug for treatment of alopecia following its impressive success rate&period;<&sol;p>&NewLine;<p style&equals;"font-weight&colon; 400&semi;">&commat;People reports&comma; in a formal announcement&comma; the FDA has <a href&equals;"https&colon;&sol;&sol;people&period;com&sol;health&sol;fda-approves-new-drug-to-treat-alopecia&sol;&quest;utm&lowbar;campaign&equals;peoplemagazine&amp&semi;utm&lowbar;content&equals;new&amp&semi;utm&lowbar;medium&equals;social&amp&semi;utm&lowbar;source&equals;twitter&period;com&amp&semi;utm&lowbar;term&equals;62a8f9a3b64e860001aa26d7">decided to approve<&sol;a> a new drug called baricitinib&comma; which is used to treat alopecia and restore hair growth&period; The oral tablet&comma; made by pharmaceutical company Eli Lilly&comma; is specifically intended to be used for those who suffer from alopecia areata—a skin disease that impacts over 6 million Americans and is known as the second most common form of hair loss&period;<&sol;p>&NewLine;<p style&equals;"font-weight&colon; 400&semi;">Baricitinib was previously approved by the FDA for the treatment of rheumatoid arthritis back in 2018&comma; however once it was used on alopecia sufferers&comma; patients saw 80&percnt; of hair regrowth in 36 weeks in comparison to just 5&percnt; of regrowth from those who took a placebo pill&period;<&sol;p>&NewLine;<p style&equals;"font-weight&colon; 400&semi;">Speaking about the latest effort to treat alopecia&comma; Dr&period; Kendall Marcus&comma; Director of Division of Dermatology and Dentistry in the FDA’s drug evaluation and research program&comma; had this to say&colon;<&sol;p>&NewLine;<blockquote>&NewLine;<p style&equals;"font-weight&colon; 400&semi;"><em> &&num;8220&semi;Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia&period; Today&&num;8217&semi;s approval will help fulfill a significant unmet need for patients with severe alopecia areata&period;&&num;8221&semi;<&sol;em><&sol;p>&NewLine;<&sol;blockquote>&NewLine;<p style&equals;"font-weight&colon; 400&semi;">Additionally&comma; late last month Concert Pharmaceuticals released its own hair loss treatment drug&period; The product reportedly had a high success rate during clinical trials&comma; with patients said to have regained at least 80&percnt; of their hair in a 24-week period&period;<&sol;p>&NewLine;<p>&nbsp&semi;<&sol;p>&NewLine;<p style&equals;"font-weight&colon; 400&semi;">Want updates directly in your text inbox&quest; Hit us up at 917-722-8057 or <a href&equals;"https&colon;&sol;&sol;my&period;community&period;com&sol;theshaderoom">click here to join&excl;<&sol;a><&sol;p>&NewLine; <div class&equals;"wpra-reactions-wrap wpra-plugin-container" style&equals;"justify-content&colon; center&semi;&semi;"> <div class&equals;"wpra-reactions-container" data-ver&equals;"1&period;3&period;10" data-post&lowbar;id&equals;"91574" data-show&lowbar;count&equals;"true" data-enable&lowbar;share&equals;"onclick" data-behavior&equals;"regular" data-animation&equals;"true" data-share&lowbar;url&equals;"https&colon;&sol;&sol;dev&period;theshaderoom&period;com&sol;new-alopecia-approved-by-the-fda&sol;" data-secure&equals;"2a1d850594"> <div class&equals;"wpra-call-to-action" style&equals;"color&colon; &num;000000&semi;font-size&colon; 25px&semi;font-weight&colon; 600&semi;">What Do You Think Roomies&quest;<&sol;div> <div class&equals;"wpra-reactions wpra-static-emojis size-medium" style&equals;"border-color&colon; &num;ffffff&semi;border-width&colon; 0px&semi;border-radius&colon; 50px&semi;border-style&colon; solid&semi;background&colon; &num;ffffff&semi;">&Tab;&Tab;&Tab;&Tab;&Tab;<div class&equals;"emoji-8 wpra-reaction wpra-pad-fix" data-count&equals;"" data-emoji&lowbar;id&equals;"8"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div><div class&equals;"emoji-10 wpra-reaction wpra-pad-fix" data-count&equals;"" data-emoji&lowbar;id&equals;"10"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div><div class&equals;"emoji-4 wpra-reaction" data-count&equals;"" data-emoji&lowbar;id&equals;"4"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div><div class&equals;"emoji-5 wpra-reaction" data-count&equals;"" data-emoji&lowbar;id&equals;"5"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div><div class&equals;"emoji-2 wpra-reaction" data-count&equals;"" data-emoji&lowbar;id&equals;"2"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div><div class&equals;"emoji-7 wpra-reaction" data-count&equals;"" data-emoji&lowbar;id&equals;"7"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div><div class&equals;"emoji-12 wpra-reaction" data-count&equals;"" data-emoji&lowbar;id&equals;"12"> <div class&equals;"wpra-plus-one">&plus;1<&sol;div>&Tab; <div style&equals;"background-color&colon; &num;ff0015" class&equals;"wpra-arrow-badge arrow-bottom-left hide-count"> <span style&equals;"border-top-color&colon; &num;ff0015" class&equals;"tail"><&sol;span> <span style&equals;"color&colon; &num;ffffff" class&equals;"count-num">0<&sol;span> <&sol;div>&Tab;<&sol;div> <&sol;div> <div class&equals;"wpra-share-wrap wpra-share-buttons-bordered" style&equals;"">&Tab;&Tab;&Tab;&Tab; <&sol;div> <&excl;-- end of share buttons -->&Tab;&Tab;&Tab; <&sol;div> <&excl;-- end of reactions container --> <&sol;div> <&excl;-- end of reactions wrap -->&Tab;&Tab;

Danielle Jennings

x